ScreenerHero

AVXL Anavex Life Sciences Corp.

NAS · US · Healthcare · Biotechnology · anavex.com
1.600USD-2.74%Mkt Cap: 148.31M $P/E: —

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and r…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap148.31M USD
Enterprise Value50.38M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.38M USD
Revenue/Share—
Last Price1.600 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.31
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.50
EPS (TTM)-0.14
EPS (Forward)-0.55
52W Range
1.5600% of range10.38
52W High10.38 USD
52W Low1.560 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-48.89%
ROA-44.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.04M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-18.25%
Net Debt-118.33M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio15.62
Quick Ratio15.51
Book Value/Sh1.21 USD
Cash/Share1.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateOct 7, 2015
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.92.70M
Float89.81M
Insiders1.71%
Institutions40.49%
Short Interest
Short Ratio20.0d
Short % Float16.09%
Short % Out.15.46%
Shares Short14.33M
Short (prev mo.)14.11M
Technical
SMA 502.802 (-42.9%)
SMA 2003.349 (-52.2%)
Beta1.14
S&P 52W Chg14.58%
Avg Vol (30d)935.96K
Avg Vol (10d)1.32M
Technical Indicators
RSI (14)16.8
MACD-0.2941
MACD Signal-0.2131
MACD Hist.-0.0810
BB Upper3.080 USD
BB Middle2.341 USD
BB Lower1.603 USD
BB Width63.10%
ATR (14)0.1642 USD
Vol Ratio (20d)1.40x